Compare Shopify Inc. (SHOP) vs Viatris Inc (VTRS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Shopify Inc. vs Viatris Inc — how do they compare? Shopify Inc. trades at $128.24 (market cap $172.54B), while Viatris Inc trades at $16.54 (market cap $19.09B). The key difference: Shopify Inc. is far larger — about 9× Viatris Inc's market cap, and Viatris Inc pays a 2.89% dividend while Shopify Inc. pays none. Which is the better fit depends on your goals.
| SHOP | VTRS | |
|---|---|---|
Market Cap | $172.54B | $19.09B |
Sector | Technology | Health |
52-Week High | $179.01 | $17.86 |
52-Week Low | $95.40 | $9.49 |
Enterprise Value | $167.77B | $31.21B |
Dividend Yield | — | 2.89% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Shopify (SHOP) trades at $134.1, down 7.57% over 24 hours, reflecting recent profit-taking after a strong August rally. The stock shows a bullish technical signal overall, with key moving averages supporting an uptrend, while oscillators remain neutral. Fundamentally, revenue growth accelerated to $11.56B in 2025, with net income reaching $1.23B and a robust gross profit margin of 47.77%. Recent news highlights strong B2B GMV growth of 76% in Q2 2026 and expansion of Shop Pay Installments in Australia, underscoring its global commerce infrastructure strength.
Outlook remains positive given accelerating revenue, expanding free cash flow margins, and dominant analyst buy ratings (65.62%), with a consensus price target of $166.84 implying significant upside. Key risks include rich valuation multiples (P/E of 98.03) and competitive pressures from giants like Amazon, but Shopify's essential role for merchants and AI-driven tools position it for long-term growth if execution continues.
Viatris (VTRS) trades at $16.61, down 1.6% on the day, showing mixed technical signals with a bullish moving average trend but neutral oscillators. The company has delivered three consecutive quarterly earnings beats, with Q2 2026 EPS of $0.69 exceeding expectations by 14.8%. However, fundamental challenges persist with negative net income margins and declining revenue trends from $16.3B in 2022 to $14.3B in 2025.
The outlook remains cautious despite recent operational improvements. While cost-cutting initiatives and strategic divestitures show progress, the stock faces headwinds from pricing pressure in generic drugs and high debt levels. Analyst consensus leans neutral with 62% hold ratings, reflecting uncertainty about the company's turnaround trajectory amid competitive and regulatory challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Shopify Inc.
Shopify Inc. provides a cloud-based commerce platform. The Company offers a platform for merchants to create an omni-channel experience that helps showcase the merchant's brand.
Read more on SHOP →About Viatris Inc
Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →
